Drug Discovery
1 item across 1 edition. First seen Thu 17 Sep, last seen Thu 17 Sep.
- Novo Nordisk announced on 16 September that it and Anthropic "will jointly address key drug discovery challenges identified by scientists and computational teams at Novo, develop targeted solutions for specific scientific challenges and workflows to support biological reasoning, and help accelerate the discovery and development of new medicines".
- The stated first step is narrow: "As an initial aim, Novo will test Claude Science for specific workflows in R&D and address scientific problems where the joint capabilities of Novo and Anthropic are expected to have the greatest impact." Novo will also use Anthropic's frontier models "to strengthen AI-driven software development".
- Mike Doustdar, president and CEO of Novo, said the partnership is "another testament to our ambition to become the world's most AI-driven healthcare company" and that "AI can help us increase productivity in R&D and compress the path from research to marketed product". Dario Amodei said AI "brings with it the potential to compress a century's worth of biological and medical breakthroughs into a decade".
- Neither company disclosed financial terms, a target count, a timeline or any benchmark, trial or dataset. The announcement reports no scientific result; the claims about productivity and timelines are the companies' own.